Major histocompatibility complex Class II-based therapy for stroke
نویسندگان
چکیده
منابع مشابه
Cellular and gene therapy for major histocompatibility complex class II deficiency.
Major histocompatibility complex (MHC) class II deficiency is a primary immunodeficiency. Lentiviral vectors are used for gene therapy in a mouse model of this disease. In addition, by a direct genetic correction approach, a diagnostic test to determine which of the four MHC II genes is defective in new MHC II-deficiency patients has been optimized.
متن کاملMajor histocompatibility complex class II and BTNL2 associations in sarcoidosis.
Infect Dis 2009; 9: 162–172. 4 Li T, Chiang JY. Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4a and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 2006; 34: 756–764. 5 Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem ...
متن کاملAntigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.
Experimental allergic encephalomyelitis is a T-cell-mediated, major histocompatibility complex (MHC) class II gene-linked autoimmune demyelinating disease of the central nervous system. To develop therapies that will specifically inactivate only the autoantigen-reactive T cells, mice were treated with soluble MHC class II molecules that had been complexed with encephalitogenic peptides. Intrave...
متن کاملMajor Histocompatibility Complex, Class I, B
Description The genes of the Human Leukocyte Antigen (HLA) system reside on chromosome 6, and code for cellsurface proteins that play a crucial role in the presentation of endogenic peptides to effector cells of the immune system. The HLA Class I protein molecule is a heterodimer, made up of two chains; a heavy one and a light one (beta 2 microglobulin). The HLA-B gene is one of the three HLA C...
متن کاملPrecise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning
We describe here a new method for predicting class II major histocompatibility complex-binding peptides, based on the preferences observed in a systematic series of peptide binding experiments where each position in a "minimal" peptide was replaced individually by every amino acid. The DRB1*0401 peptide binding preferences were determined and incorporated into a computer program that looks thro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Brain Circulation
سال: 2021
ISSN: 2394-8108
DOI: 10.4103/bc.bc_16_21